Leyla Jiang

Leyla Jiang supports clients with research and analysis that span a variety of healthcare sectors and stakeholders, where she applies her background in market access and policy analysis to a broad range of client projects.

Prior to joining Avalere, Leyla worked as a public policy manager on the central market access and government affairs team at AstraZeneca’s Beijing office, where she designed policy-driven market access strategies for AstraZeneca’s drug portfolio and managed relationships with a diverse array of stakeholders. Before that, she assisted multinational biopharmaceutical companies in a wide range of China-focused policy and market access projects in her role at a consulting firm based in Beijing.

Leyla received her MPP from Georgetown University and a BA in political science and economics from Ohio University.

Authored Content

A recent Pear Therapeutics–Avalere survey of 30 payers and 10 employer self-insured groups identified numerous insights to direct future efforts for broader adoption and coverage of prescription digital therapeutics (PDTs).

Prescription Digital Therapeutics (PDTs) are a growing and unique treatment modality that can provide expanded options for treatment to patients. As the landscape for these treatments develop across multiple therapeutic areas, challenges related to coverage, reimbursement, and access will need to be solved to advance broader adoption and utilization across key stakeholders.